Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

Summary

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Seizures
• Primary Motor Cortex
• Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
• Brain Metastases, Adult
• Brain Metastases From Extra-cranial Solid Tumors

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Ayal A. Aizer, MD

Last updated on ClinicalTrials.gov

September 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites